Phase 3 Clinical Trials With Primary Completion Dates in September 2016

This is a list of Phase 3 trials with primary completion dates in September 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACORAcorda Therapeutics, Inc.2016-09-01Phase 3NCT02271217A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke
ACRSAclaris Therapeutics, Inc.2016-09-01Phase 3NCT02667288An Open-Label Safety Study of A-101 Solution
ACRSAclaris Therapeutics, Inc.2016-09-01Phase 3NCT02667275A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
ACRSAclaris Therapeutics, Inc.2016-09-01Phase 3NCT02667236A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
ARRYArray BioPharma Inc.2016-09-01Phase 3NCT01909453Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
EARSAuris Medical Holding AG2016-09-01Phase 3NCT02040194AM-101 in the Treatment of Acute Tinnitus 3
FOLDAmicus Therapeutics, Inc.2016-09-01Phase 3NCT02384460ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
INNLInnocoll Holdings2016-09-01Phase 3NCT02447172Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
JAZZJazz Pharmaceuticals plc2016-09-01Phase 3NCT02348606"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
JAZZJazz Pharmaceuticals plc2016-09-01Phase 3NCT02348593"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
LXRXLexicon Pharmaceuticals, Inc.2016-09-01Phase 3NCT02421510Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
LXRXLexicon Pharmaceuticals, Inc.2016-09-01Phase 3NCT02384941Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
MYGNMyriad Genetics, Inc.2016-09-01Phase 3NCT01874353Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NWBONorthwest Biotherapeutics, Inc.2016-09-01Phase 3NCT00045968Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
OCULOcular Therapeutix, Inc.2016-09-01Phase 3NCT02736175Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
RIGLRigel Pharmaceuticals, Inc.2016-09-01Phase 3NCT02076412A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
RMDResMed Inc.2016-09-01Phase 3NCT01335087Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA)
TAROTaro Pharmaceutical Industries Ltd.2016-09-01Phase 3NCT02595073Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis